Public webinar 'The RECOVERY Trial: one year on'
23 March 2021
Event date and time: Wednesday 7 April 2021, 09.00 - 10.00 BST.
RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19
5 March 2021
Statement from the RECOVERY trial chief investigators, 5 March 2021
Tocilizumab reduces deaths in patients hospitalised with COVID-19
11 February 2021
RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19
15 January 2021
Statement from the RECOVERY trial chief investigators, 15 January 2021
Update on recruitment to convalescent plasma and tocilizumab treatment arms
11 January 2021
Statement from the RECOVERY trial chief investigators, 11 January 2021
RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19
14 December 2020
Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on azithromycin, 14 December 2020
RECOVERY trial shortlisted for the National Project Awards 2020 Special COVID-19 response category
30 November 2020
The RECOVERY trial has been selected as one of ten finalists in the Special COVID-19 response category in the 2020 National Project Awards, organised by PMI UK, in association with PricewaterhouseCoopers (PwC).
RECOVERY trial management acknowledged in clinical trial awards
26 October 2020
RECOVERY COVID-19 phase 3 trial to evaluate Regeneron’s REGN-COV2 investigational antibody cocktail in the UK
14 September 2020
One of the world’s largest efforts to find effective COVID-19 treatments will evaluate the impact of REGN-COV2 on mortality, hospital stays, and the need for ventilation.
No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY
29 June 2020
Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on lopinavir-ritonavir, 29 June 2020